Patient characteristics and treatment results according to initial MPN
| . | All patients . | PV . | ET . | PMF . | MPNu . | Overall P . | P (ET vs PV) . |
|---|---|---|---|---|---|---|---|
| No. of patients | 54 | 21 | 21 | 7 | 5 | ||
| Median age, y | 68.5 | 66 | 71 | 73 | 71 | NS | NS |
| JAK2 V617F positive in chronic phase, n/N (%) | 24/41 (59) | 12/14 (86) | 9/16 (56) | 2/7 (29) | 1/4 (25) | .023 | NS |
| Median time to transformation, mo | 71 | 154 | 70 | 19 | 19 | < .001 | .004 |
| AML at transformation, n (%) | 26 (48) | 13 (62) | 10 (48) | 3 (43) | 0 | NS | NS |
| MDS at transformation, n (%) | 28 (52) | 8 (38) | 11 (52) | 4 (57) | 5 (100) | ||
| Complex karyotype at transformation, n (%) | 16 (30) | 8 (44) | 6 (33) | 2 (33) | 0 | NS | NS |
| Overall response to azacitidine, n (%) | 28 (52) | 7 (33) | 15 (71) | 4 (57) | 2 (40) | NS | .016 |
| Restoration of chronic phase MPN features after azacitidine, n (%) | 11 (20) | 3 (14) | 8 (38) | 0 | 0 | NS | NS |
| Median survival from onset of azacitidine, mo | 11 | 7 | 16 | 8 | 10 | NS | NS |
| . | All patients . | PV . | ET . | PMF . | MPNu . | Overall P . | P (ET vs PV) . |
|---|---|---|---|---|---|---|---|
| No. of patients | 54 | 21 | 21 | 7 | 5 | ||
| Median age, y | 68.5 | 66 | 71 | 73 | 71 | NS | NS |
| JAK2 V617F positive in chronic phase, n/N (%) | 24/41 (59) | 12/14 (86) | 9/16 (56) | 2/7 (29) | 1/4 (25) | .023 | NS |
| Median time to transformation, mo | 71 | 154 | 70 | 19 | 19 | < .001 | .004 |
| AML at transformation, n (%) | 26 (48) | 13 (62) | 10 (48) | 3 (43) | 0 | NS | NS |
| MDS at transformation, n (%) | 28 (52) | 8 (38) | 11 (52) | 4 (57) | 5 (100) | ||
| Complex karyotype at transformation, n (%) | 16 (30) | 8 (44) | 6 (33) | 2 (33) | 0 | NS | NS |
| Overall response to azacitidine, n (%) | 28 (52) | 7 (33) | 15 (71) | 4 (57) | 2 (40) | NS | .016 |
| Restoration of chronic phase MPN features after azacitidine, n (%) | 11 (20) | 3 (14) | 8 (38) | 0 | 0 | NS | NS |
| Median survival from onset of azacitidine, mo | 11 | 7 | 16 | 8 | 10 | NS | NS |
PV indicates polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; MPNu, myeloproliferative neoplasm unclassified; NS, not significant; JAK2, Janus kinase-2; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; and MPN, myeloproliferative neoplasm.